Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Ann Allergy Asthma Immunol. 2013 Apr;110(4):290-4. doi: 10.1016/j.anai.2013.01.013. Epub 2013 Feb 14.
Oral desensitization in children allergic to cow's milk proteins is not risk free. The analysis of factors that may influence the outcome is of utmost importance.
To analyze the efficacy and safety of the oral desensitization according to specific IgE (sIgE) level and adverse events during the maintenance phase.
Thirty-six patients allergic to cow's milk (mean age, 7 years) were included in an oral desensitization protocol. Patients were grouped according to sIgE levels (ImmunoCAP) into groups 1 (sIgE <3.5 kU/L), 2 (3.5-17 kU/L), and 3 (>17-50 kU/L). Nineteen children were included as a control group. Serum sIgE levels to cow's milk and its proteins were determined at inclusion and 6 and 12 months after finishing the desensitization protocol.
Thirty-three of 36 patients were successfully desensitized (200 mL): 100% of group 1 and 88% of groups 2 and 3. Desensitization was achieved in a median of 3 months (range, 1-12 months); 90% of the patients in group 1, 50% of the patients in group 2, and 30% of the patients in group 3 achieved tolerance in less than 3 months (P = .04). In the control group only 1 child tolerated milk in oral food challenge after 1 year. During the induction phase, there were 53 adverse events in 27 patients (75%). Patients of groups 2 and 3 had more severe adverse events compared with group 1. During the maintenance phase, 20 of 33 patients (60%) had an adverse event.
Oral desensitization is efficacious. Tolerance is achieved earlier when sIgE is lower. Severe adverse events are frequent, especially in patients with higher sIgE levels.
儿童对牛奶蛋白过敏进行口服脱敏治疗并非没有风险。分析可能影响治疗结果的因素至关重要。
根据特定免疫球蛋白 E(sIgE)水平和维持阶段的不良事件分析口服脱敏治疗的疗效和安全性。
将 36 例牛奶过敏患儿(平均年龄 7 岁)纳入口服脱敏方案。根据 sIgE(免疫捕获)水平将患者分为 3 组:1 组(sIgE <3.5 kU/L)、2 组(3.5-17 kU/L)和 3 组(>17-50 kU/L)。另外 19 例患儿作为对照组。在纳入和完成脱敏方案后 6 个月和 12 个月时,测定血清 sIgE 水平和牛奶及其蛋白。
36 例患者中有 33 例成功脱敏(200 mL):1 组患者 100%,2 组和 3 组患者分别为 88%。脱敏中位时间为 3 个月(1-12 个月);1 组 90%、2 组 50%和 3 组 30%的患者在 3 个月内达到耐受(P =.04)。在对照组中,1 年后仅 1 例患儿口服食物挑战后耐受牛奶。诱导阶段 27 例患者(75%)共发生 53 次不良事件。2 组和 3 组患者不良事件更严重。维持阶段 33 例患者中有 20 例(60%)出现不良事件。
口服脱敏治疗有效。sIgE 较低时,更早达到耐受。严重不良事件较为常见,尤其在 sIgE 水平较高的患者中。